The European Gazette
SEE OTHER BRANDS

The latest news from Europe

The European Gazette: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The European Gazette.

Press releases published on April 9, 2025

Aegon announces reset of perpetual subordinated bonds

Aegon announces reset of perpetual subordinated bonds

The Hague, April 9, 2025 - Aegon today announces that it will reset the coupon on its EUR 113 million (NLG 250 million) 1.506% perpetual cumulative subordinated bonds (ISIN: NL0000120004, originally issued in 1995, the “bonds”) on June 8, 2025. As of June …

Management Increasing Ownership in Amaroq Minerals and RSU Vesting Update

Management Increasing Ownership in Amaroq Minerals and RSU Vesting Update

Reykjavík, April 09, 2025 (GLOBE NEWSWIRE) -- "Amaroq" or the "Company" Management increasing ownership in Amaroq Minerals And Vesting under the Restricted Share Unit Plan (the “RSU Plan”) and PDMR purchases TORONTO, ONTARIO – 09 April 2025 – Amaroq …

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – …

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 Présentation de nouvelles données cliniques sur les bénéfices et la sécurité à long terme de l’anticorps monoclonal …

SBM Offshore signs US$400 million Sale and Leaseback agreement for FPSO Cidade de Paraty

SBM Offshore signs US$400 million Sale and Leaseback agreement for FPSO Cidade de Paraty

Amsterdam, April 9, 2025 SBM Offshore announces it has signed a non-recourse sale and leaseback financing agreement for FPSO Cidade de Paraty for the total amount of US$400 million and with a tenor of 8 years. The transaction is expected to be completed …

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life- …

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Saint Herblain (France) et Schlieren (Zurich), le 9 avril 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, et LimmaTech Biologics AG, société de biotechnologies développant des vaccins pour la prévention de …

Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors

Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors

New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board member Significant leadership experience will be instrumental as Augustine transitions into a clinical-stage company …

AMG Approves US Chrome Manufacturing Plant

AMG Approves US Chrome Manufacturing Plant

Amsterdam, 9 April 2025 --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that the Management Board has approved a capital investment of USD $15 million to establish an aluminothermic production facility to …

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX …

US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food …

Stallion Uranium Increases Private Placement to $1.45 Million

Stallion Uranium Increases Private Placement to $1.45 Million

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, April 09, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service